In contrast with the historically poor responses to second-line treatments for CCA, we demonstrated the continued clinical benefit of pemigatinib in previously treated CCA with FGFR2 fusions or rearrangements over an extended follow-up period. Here, FGFR2 is linked to cholangiocarcinoma.